Biotech Business - September 29, 2021
XNK Therapeutics further expands its pipeline
XNK Therapeutics has announced plans to further expand the scope of its technology platform of natural killer (NK) cell therapies outside of multiple myeloma to also include other cancer indications to broaden the pipeline. The company will begin the preclinical and commercial work to expand the pipeline and expects to announce a decision in Q1 […]
Biotech Business - September 20, 2021
Intrance Medical Systems raises 8 million USD
Intrance Medical Systems Inc, a subsidiary of Sweden-based Intrance Holdings AB, has secured financing from Swedish real estate investor Erik Selin through his private company, Erik Selin Fastigheter AB. Erik Selin has agreed to become the anchor investor as part of a Series A financing round of 15 million USD, becoming the largest shareholder next […]
Biotech Business - September 17, 2021
Bioneer enters strategic collaboration
Bioneer has announced a strategic collaboration with the National Biologics Facility (NBF) to commercialize their combined CRO services for mammalian expression of recombinant proteins. The entity, previously named CHO CORE, is one of the largest academic groups in the world working on Chinese Hamster Ovary cell (CHO) modelling and mechanisms. Funded by the Novo Nordisk […]
Biotech Business - September 16, 2021
The FDA extends the PDUFA goal date for Calliditas’ NDA
Calliditas Therapeutics has announced that the U.S. Food and Drug Administration has extended the PDUFA goal date for its New Drug Application (NDA) seeking accelerated approval for Nefecon to December 15, 2021. In March 2021 Calliditas filed for FDA approval using the Accelerated Approval Program, based on the proteinuria endpoint as previously discussed with the […]
Biotech Business - September 14, 2021
Sprint Bioscience adds new cancer drug program to its pipeline
Sprint Bioscience is broadening its pipeline with an additional drug program for the treatment of solid tumors. The program goes by the program name NIMA and aims to develop drugs to inhibit a naturally occurring protein that is associated with poor survival in several different forms of cancer, states the company. “We have once again […]
Biotech Business - September 9, 2021
Diamyd Medical raises 150 million SEK
Diamyd Medical has successfully completed a directed share issue of 5 357 143 B-shares at a price of SEK 28 per share. Through the Directed Share Issue, the company will receive gross proceeds of SEK 150 million. The Directed Share Issue was subscribed by qualified investors, states the company. ”The company is developing strongly and […]
